Licensing sought for AIDS prevention pills in EU
Print Edition
EUROPE’S medicines watchdog said yesterday it has recommended the licensing of the first-ever AIDS prevention pill for the European Union.
Dubbed Truvada, the pill combines two drugs and is already used in Europe and elsewhere in the world as part of AIDS treatment, and is approved in the United States, Kenya and South Africa as a preventive “pre-exposure prophylaxis” or PrEP.
Now the European Medicines Agency has also “recommended granting a marketing authorization in the European Union for Truvada... for pre-exposure prophylaxis.”
The medicine must be used “in combination with safer sex practices to reduce the risk” of picking up HIV, it added.
PrEP is a way for people at high risk of infection, including men who have sex with men, and heterosexual couples of whom one partner has the virus, to lower their chances of getting HIV.
Two recent studies had found “substantial reductions” in infection risk with Truvada, an EMA statement said.
In one study, risk was lowered by 42 percent in homosexual men, and another by 75 percent in heterosexual couples with one HIV-positive partner.
The recommendation of the EMA’s Committee for Medicinal Products for Human Use will be forwarded to the European Commission, the EU’s executive arm, for approval.
Each member state will then take a decision on price, and whether or not it will be covered by national health systems, the EMA said. EU member France already announced last November it would make the drug available as PrEP for free, under a temporary national authorisation.
Truvada is manufactured by US pharmaceutical group Gilead.
With no vaccine or cure for AIDS, the focus remains on prevention.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
